Health

Patients Can Soon Get Weight Loss Drugs Direct From Lilly

Platform will connect patients with doctors for scripts
Drugmaker says selling directly might reduce high costs

Obesity Drugs: Global Sales Could Hit $80 Billion in 2030

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Madison Muller

January 4, 2024 at 8:20 AM EST

Updated on

January 4, 2024 at 1:26 PM EST

This article is for subscribers only.

Eli Lilly & Co. launched a service to sell its weight-loss drugs directly to the public. That pits the company against startups such as Ro and Noom that have fed the frenzy over GLP-1 medications by making them easy to access online.

The drugmaker’s new digital health-care platform, dubbed LillyDirect, will help connect patients with obesity, diabetes and migraines to doctors who can prescribe medications including Mounjaro and Zepbound, the company said in a statement Thursday. It will also offer direct home delivery of certain drugs through third-party pharmacies, Lilly has partnered with closely-held Form Health Inc., a virtual weight loss program, on obesity and will work with 9amHealth Inc on its diabetes offerings.